Foto del docente

Federico Magnani

PhD Student

Department of Medical and Surgical Sciences

Curriculum vitae

I’m currently pursuing a PhD in medical biotechnologies, focused on infectious diseases at high epidemic risk. The course, led by the Univesity of Siena, is a very interdisciplinary project joining 13 italian universities.

My approach to immunology and epidemiology is algorithmic, mathematical and data-driven. Combining the microbiological technologies to the computational revolution, I apply Machine Learning and Artificial Intelligence to biomedicine, inspired by the work of scientists like Prof. A. Vespignani and Sir D. Hassabis.

This transversality made me extremely interested in the Cambridge Centre for AI in Medicine, in which I’m passing 6 months.

 

Education

  • National PhD student Nov 2023 - Currently
    National PhD course focused on the emergence and diffusion of epidemic infections, vaccine response and antibiotic-resistance, through mathematical modeling and Machine Learning. Collaboration coordinated by the University of Siena. 

  • Research collaboration Nov 2022 - Nov 2023
    Research collaboration with the Department of Medical and Surgical Sciences (DIMEC) of the University of Bologna.
  • Master thesis with UPM Feb-Jun 2022
    Research activity at the Universidad Politecnica de Madrid (UMP, Madrid, Spain), hosted by the GAPS informatic engineering group, where I developed my thesis about the application of network science to the task of drug repurposing.
  • Master in Applied Physics 2019 - 2022
    Master degree in Applied Physics (Alma Mater Studiorum, University of Bologna).
    Curriculum focused on Computer Science.
  • Bachelor in Physics 2015 - 2019
    Bachelor degree in Physics (Alma Mater Studiorum, University of Bologna) with a thesis focusing on atmospheric physics (cirrus cloud's spectral emission analysis).
  • Classical Studies 2010 - 2015
    High school degree in classical studies (Liceo Classico Giulio Cesare - Manara Valigmigli, Rimini).

 

Latest news

At the moment no news are available.